| 2021 |
8-2 |
08.11 |
- Approved the 2021 Q2 Surplus Earnings Distribution.
|
| 2021 |
8-1 |
07.07 |
- 通過達爾膚投資控股股份有限公司為董事長案。
- 通過委任第四屆薪資報酬委員會成員案。
- 通過與國立中正大學簽訂產學合作及學術回饋機制契約。
|
| 2021 |
7-21 |
06.17 |
- 通過本公司因應疫情延期召開110年股東常會，股東會之日期及地點。
|
| 2021 |
7-20 |
05.07 |
- Approved the 2021 Q1 Surplus Earnings Distribution.
- Approved the resolution cash distributed from capital surplus to shareholders
|
| 2021 |
7-19 |
03.05 |
- Approved the 2020 compensation distribution plan for employees and directors about the amount and form.
- Approved Business Report and Financial Statements of 2020.
- Approved the 2020 Surplus Earnings Distribution.
- Approved the 2020 Statement on Internal Control System.
- Approved the 2021 Shareholders’meeting date, place, agenda and proposal
- Approved the 2021 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
|
| 2020 |
7-18 |
12.18 |
- Approved the 2021 annual budget.
|
| 2020 |
7-17 |
11.10 |
- Approved subsidiary Wclinic Biotechnology Corporation(Samoa) disposal of shares in Jiangsu DR. WU Cosmetics Co., Ltd.
|
| 2020 |
7-16 |
11.06 |
- Approved the 2020 Q3 Surplus Earnings Distribution.
|
| 2020 |
7-15 |
10.23 |
- Approved subsidiary Wclinic Biotechnology Corporation, it plans to invest in the establishment of an overseas BVI subsidiary.
|
| 2020 |
7-14 |
08.07 |
- Approved the 2020 Q2 Surplus Earnings Distribution.
|
| 2020 |
7-13 |
05.06 |
- Approved the 2020 Q1 Surplus Earnings Distribution.
|
| 2020 |
7-12 |
03.13 |
- Approved the 2019 compensation distribution plan for employees and directors about the amount and form.
- Approved Business Report and Financial Statements of 2019.
- Approved the 2019 Surplus Earnings Distribution.
- Approved the 2019 Statement on Internal Control System.
- Approved the 2020 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
|
| 2019 |
7-11 |
12.24 |
- Approved the 2020 annual budget.
- Approved the 2020 auditing plans for the Company and its subsidiary.
- Approved the 2019 evaluation of the CPA’s independence and suitability.
- Approved the resolution cash distributed from capital surplus to shareholders.
- Approved the amendment to “Articles of Incorporation.
- Approved the 2020 First extraordinary general meeting date and place.
|
| 2019 |
7-10 |
11.07 |
- Reported the third quarter 2019 consolidated financial statements.
- Approved the subsidiary Wclinic Biotechnology capital reduction to cover losses.
|
| 2019 |
7-9 |
08.06 |
- Reported the second quarter 2019 consolidated financial statements.
- Approved the amendment to the "Operational Procedures for Loaning of Company Funds.
- Approved the amendment to the "Operational Procedures for Endorsements and Guarantees.
- Approved the amendment to the "Policies and systems for compensation of the directors and functional committees.
- Approved the subsidiary Wclinic Biotechnology capital reduction to cover losses.
- Approved the subsidiary Wclinic Biotechnology capital reduction and return to parent company.
|
| 2019 |
7-8 |
05.09 |
- Reported the first quarter 2019 consolidated financial statements.
- Approved the appointment of managers.
|
| 2019 |
7-7 |
02.26 |
- Approved the 2018 compensation distribution plan for employees and directors about the amount and form.
- Approved Business Report and Financial Statements of 2018.
- Approved the 2018 Deficit Compensated.
- Approved the 2018 Statement on Internal Control System.
- Approved the amendment to the Operational Procedures for Acquisition and Disposal of Assets.
- Approved the change of business place of the Company.
- Approved the 2019 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
- Approved the resolution cash distributed from capital surplus to shareholders.
|
| 2018 |
7-6 |
12.24 |
- Approved the investment of Dr. Wu Skincare (Jiangsu) Co., Ltd.
- Approved the equity disposal of Dr. Wu Skincare (Shanghai) Co., Ltd.
|
| 2018 |
7-5 |
12.13 |
- Approved the 2019 annual budget.
- Approved the 2019 auditing plans for the Company and its mainland subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd.
- Approved the 2018 evaluation of the CPA’s independence and suitability.
|
| 2018 |
7-4 |
11.08 |
- Approved the application for Complaint Procedures.
- Approved the accounts receivable are restated as other accounts receivable considered as fund loaning.
- Approved the compensation for the CFO.
|
| 2018 |
7-3 |
09.20 |
- Approved the increase in capital for Dr. Wu Skincare (Shanghai) Co., Ltd.
|
| 2018 |
7-2 |
08.13 |
- Approved the appointment members of the third session of compensation committee.
- Approved the accounts receivable are restated as other accounts receivable considered as fund loaning.
|
| 2018 |
7-1 |
06.21 |
- Approved Mr. Eric Wu as Chairman.
|
| 2018 |
6-22 |
05.10 |
- Approved the appointment of the CFO.
- Approved the appointment of the Internal Audit Manager.
- Approved the record date of capital reduction for the cancellation of treasury shares.
- Approved the accounts receivable-related party are restated as other accounts receivable.
- Approved the submission of examination of nominated directors (including independent directors) candidate list to board of directors.
- Approved the exemption from non-compete clause for new directors (including independent directors).
|
| 2018 |
6-21 |
03.08 |
- Approved the 2017 compensation distribution plan for employees and directors about the amount and form.
- Approved Business Report and Financial Statements of 2017.
- Approved the 2017 Surplus Earnings Distribution.
- Approved the 2017 Statement on Internal Control System.
- Approved the loan to the Company’s subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd.
- Approved the accounts receivable-related party are restated as other accounts receivable, shall be recognized as fund loaning.
- Approved the re-elections of directors (inculding independent directors).
- Approved the propose of candidates for directors (including independent directors) to be nominated by the Board of Directors.
- Approved the 2018 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
|
| 2018 |
6-20 |
01.10 |
- Approved the repurchasing of Company’s stocks.
|
| 2017 |
6-19 |
12.14 |
- Approved the 2018 annual budget.
- Approved the 2018 auditing plans for the Company and its mainland subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd.
- Approved the 2017 evaluation of the CPA’s independence and suitability.
|
| 2017 |
6-18 |
11.09 |
- Reported the Third quarter 2017 consolidated financial statements.
- Approved the amendments to Audit Committee Charter、Rules of Procedure for Board of Directors Meetings and Rules Governing the Scope of Powers of Independent Directors.
- Approved the Company’s subsidiary Dr.Wu Skincare (Shanghai) Co., Ltd. investment to set up subsidiary.
|
| 2017 |
6-17 |
08.10 |
- Reported the second quarter 2017 consolidated financial statements.
- Approved the change of business place of the Company.
|
| 2017 |
6-16 |
03.10 |
- Approved the Company’s ex-dividend-date.
- Approved the appointment of a deputy G.M.
|
| 2017 |
6-15 |
03.10 |
- Reported the first quarter 2017 consolidated financial statements.
- Approved the evaluation of the list of nominated candidates for directors to the Board.
- Approved the 2016 compensation distribution plan for managers.
|
| 2017 |
6-14 |
03.10 |
- Approved the 2016 compensation distribution plan for employees and directors about the amount and form.
- Approved Business Report and Financial Statements of 2016.
- Approved the 2016 Surplus Earnings Distribution.
- Approved the 2016 Statement on Internal Control System.
- Approved the amendments to the Settlement Procedures for the Acquisition and Disposal of Assets.
- Approved the loan to the Company’s subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd.
- Approved the Company’s cooperation with Price Waterhouse Coopers (PwC) Taiwan for auditor rotation.
- Approved the by-election of one director and the proposed candidates for directors to be nominated by the Board of Directors.
- Approved the 2017 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
|
| 2016 |
6-13 |
12.19 |
- Approved the 2017 annual budget.
- Approved the 2016 auditing plans for the Company and its mainland subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd.
- Approved the 2016 evaluation of the CPA’s independence and suitability.
- Approved the appointment of the CFO.
- Approved the compensation for the CFO.
|
| 2016 |
6-12 |
11.07 |
- Reported the third quarter 2016 consolidated financial statements.
- Approved the increase in capital for Dr. Wu Skincare (Shanghai) Co., Ltd.
|
| 2016 |
6-11 |
08.08 |
- Reported the second quarter 2016 consolidated financial statements.
|
| 2016 |
6-10 |
05.20 |
- Approved the appointment of a deputy financial director.
|
| 2016 |
6-9 |
05.12 |
- Approved the Company’s ex-rights date, ex-dividend-date and capital increase date.
- Approved the appointment of managers.
- Approved the compensation for managers.
- Approved the 2015 compensation distribution plan for managers.
- Approved the issuance of new shares through cash distribution to managers before listing on the OTC market.
|
| 2016 |
6-8 |
03.07 |
- Approved the 2015 compensation distribution plan (i.e. amount and form) for employees and directors.
- Approved the 2015 Business Report and Financial Statements.
- Approved the 2015 Statement on Internal Control System.
- Approved the 2015 Surplus Earnings Distribution.
- Approved the Issuance of New Common Shares for Capital Increase through Retained Earnings.
- Approved the Issuance of New Common Shares for Capital Increase through Cash.
- Approved the change of CFO and spokesperson.
- Approved the loan to subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd.
- Approved the application for suspension and resumption of trading procedures.
- Approved the new agenda and amendments to the 2016 Shareholders’ Meeting.
|
| 2016 |
6-7 |
01.21 |
- Approved the 2016 Shareholders’ meeting date, place, agenda and proposal made by shareholders with over 1% share.
|
